
Teva's American Dream Boat is Sinking
08.08.18|Uri Tal-TeneOver the past six quarters Teva's North American sales have been in free fall. The company's operating profit is in even worse shape. Mylan's decision to slash the price tag on its generic Copaxone offering further threatens Teva's revenues, meaning the company must hurry to provide the three potential trump cards it has up its sleeve